Presentation is loading. Please wait.

Presentation is loading. Please wait.

Arrhythmias: The Good, the Bad and the Ugly

Similar presentations


Presentation on theme: "Arrhythmias: The Good, the Bad and the Ugly"— Presentation transcript:

1 Arrhythmias: The Good, the Bad and the Ugly
Soori Sivakumaran MD, FRCPC Clinical Associate Professor of Medicine University of Alberta October 4, 2014

2 What is this rhythm?

3

4

5 Ventricular Tachycardia
History of previous MI or cardiomyopathy Abnormal cardiac exam Family history of sudden/premature cardiac death A slow rate doesn’t mean its not VT

6

7

8

9

10 Supraventricular Tachycardias
Atrial fibrillation Atrial flutter Atrial tachycardia Multifocal atrial tach Junctional tachycardia AV nodal re-entry AV re-entry tachycardia Murgatroyd, Krahn Yee Skanes and Klein

11 History Previous heart disease Onset Associated symptoms Termination
Regular or irregular Chest discomfort, SOB, lightheaded, syncope Termination Spontaneous or by patient maneuvers

12 ECG Criteria What is the heart rate? Are there P waves?
Is the rhythm regular or irregular? What is the relationship of P waves to QRS complexes? Are the QRS complexes wide or narrow?

13 Sinus Tachycardia Most common fast rhythm
Response to another condition Treat primary problem (sepsis, pain etc.) Do not treat tachycardia! Murgatroyd, Krahn Yee Skanes and Klein

14

15

16 AVRT vs AVNRT Murgatroyd, Krahn Yee Skanes and Klein

17

18

19

20

21 Atrial fibrillation can keep bad company
Hypertension Pulmonary embolus Cardiomyopathy Valvular heart disease Ischemia Thyrotoxicosis Pericarditis Murgatroyd, Krahn Yee Skanes and Klein

22 Anticoagulation prevents strokes
Valvular AF Stroke Risk Factors (Non Valvular AF) Age over 65 Hypertension Diabetes Previous Stroke or TIA Structural Heart Disease

23 Anticoagulation prevents strokes
Warfarin reduces the risk of stroke by 2/3 ASA reduces the risk of stroke 30% Recommended in non valvular AF with no stroke risk factors but arterial vascular disease INR target 2.0 to 3.0 Newer oral anticoagulants an alternative

24 Electrical and chemical cardioversion have the same risk of stroke
CV safe within 48 hours of the onset of atrial fibrillation Do not start anti-arrhythmic drugs that may cardiovert the patient beyond this window After 3 weeks of anticoagulation with the INR between 2.0 and 3.0 CV safe following a TEE to rule out LA thrombus

25 Rate Control Usually safest strategy in ER
Digoxin is a poor rate control agent unless patient is at rest Beta blocker and calcium channel blockers much more effective for rate control Digoxin can be used in combination with above and in patients in acute CHF

26 Rate control = Rhythm control
Misconceptions People live longer if sinus rhythm is maintained The risk of stroke is less if sinus rhythm is maintained

27 Atrial Fibrillation: Follow-up Investigation of Rhythm Management (AFFIRM)
Primary Endpoint - Total Mortality 5 10 15 20 25 30 1 2 3 4 Mortality (%) Rate Rhythm p = Time (Years) Rhythm: 2033 1932 1807 1316 780 255 Rate: 2027 1925 1825 1328 774 236 AFFIRM Investigators N Engl J Med 347: , 2002

28 Symptoms determine whether to pursue a rhythm control strategy
Patients with atrial fibrillation have a wide range of symptoms Patients are more likely to have symptoms: Younger Female Paroxysmal AF LVH CHF

29 Symptoms determine whether to pursue a rhythm control strategy
Common Symptoms Palpitations Dyspnea Fatigue Decreased exercise tolerance The degree of symptoms may not be clear until the patient is back in sinus rhythm

30 Antiarrhythmic drugs can be pro-arrhythmic
Class I and III antiarrhythmic drugs are potentially proarrhythmic VF is worse than AF Contraindicated in patients with structural heart disease Need to rule out structural heart disease and ischemia and other factors before using

31 Asymptomatic PAF is common
Many patients have who have symptomatic episodes of atrial fibrillation also have asymptomatic episodes of atrial fibrillation Cannot use symptoms to determine that AF is not recurring Probably safest to continue anticoagulation indefinitley in most cases For stroke risk, PAF = CAF

32 Anti-arrhythmic Rx should be stopped in chronic atrial fibrillation
Risks with no benefit Rate control agents Continue anticoagulation with monitoring (maybe affected by discontinuation)

33

34

35 AF with Pre-Excitation
Murgatroyd, Krahn Yee Skanes and Klein

36

37 Conclusions Record the rhythm on 12 lead ECG
Consider running 12 lead rhythm strip with CSM or adenosine The presence of structural heart disease greatly increases the risk of ventricular arrhythmias Don’t use amiodarone IV for everything


Download ppt "Arrhythmias: The Good, the Bad and the Ugly"

Similar presentations


Ads by Google